Kite Pharma, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of cell therapy innovation. Founded in 2009, Kite has made significant strides in the development of chimeric antigen receptor (CAR) T-cell therapies, primarily targeting cancer treatment. With a strong operational presence across North America and Europe, the company focuses on harnessing the power of the immune system to combat malignancies. Kite's flagship products, including Yescarta, are distinguished by their ability to provide personalised treatment options for patients with certain types of blood cancers. The company has achieved notable recognition within the industry, establishing itself as a pioneer in the field of oncology. With a commitment to advancing cell therapy, Kite Pharma continues to shape the future of cancer treatment, positioning itself as a key player in the biopharmaceutical landscape.
We don't have data for Kite Pharma, Inc., but we can show you information about their parent organization instead.
View parent company